Western University

Scholarship@Western
Paediatrics Publications

Paediatrics Department

1-1-2020

Presence of benznidazole conjugated metabolites in urine
identified by β-glucuronidase
-glucuronidase treatment
María Elena Marson
Facultad de Ciencias Exactas, Universidad Nacional de La Plata

Facundo García Bournissen
Hospital de Ninos Ricardo Gutierrez

Jaime Altcheh
Hospital de Ninos Ricardo Gutierrez

Guillermo Moscatelli
Hospital de Ninos Ricardo Gutierrez

Samantha Moroni
Hospital de Ninos Ricardo Gutierrez

See next page for additional authors

Follow this and additional works at: https://ir.lib.uwo.ca/paedpub
Part of the Pediatrics Commons

Citation of this paper:
Marson, María Elena; Bournissen, Facundo García; Altcheh, Jaime; Moscatelli, Guillermo; Moroni,
Samantha; and Mastrantonio, Guido Enrique, "Presence of benznidazole conjugated metabolites in urine
identified by β-glucuronidase treatment" (2020). Paediatrics Publications. 1334.
https://ir.lib.uwo.ca/paedpub/1334

Authors
María Elena Marson, Facundo García Bournissen, Jaime Altcheh, Guillermo Moscatelli, Samantha Moroni,
and Guido Enrique Mastrantonio

This article is available at Scholarship@Western: https://ir.lib.uwo.ca/paedpub/1334

http://dx.doi.org/10.1590/s2175-97902019000218034

Presence of benznidazole conjugated metabolites in urine
identified by β-glucuronidase treatment
María Elena Marson

*, Facundo García Bournissen3,4, Jaime Altcheh3,4, Guillermo Moscatelli3,
Samantha Moroni3, Guido Enrique Mastrantonio1,2,4

1,2,4,

Area de Toxicología, Departamento de Ciencias Biológicas, Facultad de Ciencias Exactas. Universidad Nacional de La
Plata. La Plata, Provincia de Buenos Aires, Argentina, 2PlaPiMu-LaSeiSiC. Universidad Nacional de La Plata / Comisión de
Investigaciones Científicas de la Provincia de Buenos Aires, Argentina, 3Parasitología Chagas. Hospital de Niños Ricardo
Gutiérrez, Ciudad Autónoma de Buenos Aires, Argentina, 4Consejo Nacional de Investigaciones Científicas y Técnicas
(CONICET).
1

Chagas disease is a serious public health problem in Latin America and, due to migration, in other nonendemic regions. Benznidazole (BNZ) is first choice drug in pediatric therapeutics. However, little is
known regarding its metabolism in humans. The aim of the study was to isolate and identify products
of human BZN metabolism in urine samples obtained from a pediatric Chagas patient and a healthy
adult volunteer both treated with BZN. Urine samples were collected after dose of BNZ. Urine was
treated with β-glucuronidase followed by an extraction procedure under two different pH conditions
and a HPLC/UV and MS/MS identification of BZN and its metabolites. BZN (m/z 260.09847) was
identified in all urine extracts. Peaks from each extracted chromatograms were selected for MS and
MS/MS identification. Three compounds structurally related to BZN were identified: BZN-Na+ (m/z
283.08009), N-amine-BZN (m/z 230.12307) and N-hydroxi-amine-BZN (m/z 246.11702). BNZ-Na+
was identified in all extracts, but N-amine-BZN and N-hydroxi-amine-BZN were only observed in those
extracts treated with β-glucuronidase. This is the first experimental report showing elimination of BZN
N-reduced metabolites in urine. As they were released after treatment with β-glucuronidase it can be
suggested that glucuronization plays a role in BNZ metabolism and renal elimination.
Keywords: Benznidazole metabolites. Chagas Disease/drug therapy. Glucuronidase/urine. High
Performance Liquid Chromatography HPLC/methods. Mass Spectrometry/ methods. Antiparasitic
agents/pharmacology.

INTRODUCTION
Chagas disease is one of the most neglected diseases
in the world with approximately 10 million people infected
in Latin America, where it is endemic. It is a zoonosis
caused by infection with the parasite Trypanosoma cruzi
(Schmunis, 2007; Urbina, Docampo, 2003). It has also
expanded to non-endemic regions such as North American
and European countries via migration of infected
individuals (Schmunis, 1995WHO, 2002). For the past
40 years only two drugs, nifurtimox and benznidazole
(BNZ), have been available for the treatment of Chagas
disease, both with similar effectiveness and frequency of
*Correspondence: María Elena Marson. Campus Tecnológico CIC, Camino
Centenario e/505 y 508 (1897), Gonnet, Provincia de Buenos Aires. Argentina.
Telephone: +54 221 5071291. E-mail: emarson@biol.unlp.edu.ar
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adverse drug reactions (ADRs). However, they have long
been used without a clear understanding of mechanisms
of action, pharmacokinetics or toxicokinetics.
The mechanism of action of BZN (N-benzyl-2nitroimidazole acetamide) is still not clear, but involves
activation by a parasite nitroreductase (Hall, Wilkinson,
2012) to reactive metabolites that can induce reductive
stress and covalent modification of proteins and other
macromolecules in T. cruzi, disrupting parasite metabolism
and function (Docampo, 1990; Moreno et al., 1982; Urbina,
Docampo, 2003). To date, virtually nothing is known about
the elimination pathways for BNZ in humans, it is assumed
to be eliminated by the liver, with <20% of the drug excreted
unchanged by the kidney, however, virtually no information
has been produced in humans (Raaflaub, Ziegler, 1979;
Raaflaub, 1980; Lau et al., 1992), and little metabolism
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information is available from animal studies (Moreno et al.,
1982; Richle, Raaflaub, 1982; Workman et al, 1984; Lee,
Workman, 1986; Workman, Walton, Lee, 1986; Lee,
Workman, Cheeseman, 1987; Walton, Workman, 1987).
The aim of this study was to isolate and identify
products of human BZN metabolism in urine samples,
including identification of conjugated products, by
treating samples with β-glucuronidase. The experiments
with β-glucuronidase and aril-sulfatase could give us
the initial information about the presence of phase II
BZN metabolites in the human urine samples. Both
these enzymes converted the phase II BZN metabolites
(conjugates of xenobiotics with glucuronic acid or sulfate)
back to the phase I BZN metabolites.

MATERIAL AND METHODS
Reagents

Trichloroacetic acid (TCA) and dichloro methane
(DCM) were purchased from Biopack (Buenos Aires,
Argentina). Dimethyl sulfoxide (DMSO), anhydrous
sodium sulfate, sodium dihydrogen phosphate
dodecahydrate, potassium dihydrogenphosphate and
sodium hydroxide were obtained from Anedra (Buenos
Aires, Argentina). Hydrochloric acid and formic acid
was obtained from J.T. Baker (USA). All reagents were
analytic grade. Chromatographic grade demineralized
water (<0.2 μsiemens) was obtained in our laboratory
with ionic exchange resins. For pH measures a pH-meter
from Altronix TPXII, and commercial pH test strips from
Universal indicator Merck were used.
High-performance liquid chromatography HPLCgrade acetonitrile (J.T. Baker, USA) was used. Pure BNZ
was obtained from Hoffmann-La Roche Ltd. (Buenos
Aires, Argentina).
Helix pomatia (HP) β-glucuronidase (EC 3.2.1.31,
type HP-2, 100,000 units/mL) with aril-sulfatase activity
(EC 3.1.6.1, 7,500 units/mL) and a β-glucuronidase
from Recombinant Escherichia coli BL21 (EC 3.2.1.31,
20,000,000 units/gr) (without aril-sulfatase activity) were
obtained from Sigma Aldrich, USA. A phosphate buffer
(pH 6.5) was prepared by mixing 800.0 mL of 0.067M
sodium hydrogenphosphate dodecahydrate and 200.0 mL
of 0.065M potassium dihydrogenphosphate and adjusted
with hydrochloric acid.
BZN Stock and Working Solutions

BNZ stock solution was prepared with 112.8 mg
of BNZ in 5 mL of DMSO to complete dissolution and
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then accurately diluted with acetonitrile to 25.00 mL in
a calibrated volumetric flask to obtain a 4.512 mg/mL
solution. Stock solution was fractionated and stored at 4 °C
and -21 °C, and stability chromatographically evaluated
from three to six months at both temperatures. Variable
volumes of the BNZ stock solution were diluted in the
mobile phase to obtain BZN working solutions.
HPLC - UV/MS/MS instrumentation

Urine samples were initially analyzed by HPLC/
UV for BNZ quantification at 313 nm. Then, the extracts
were analyzed by HPLC/UV for BZN and BZN metabolite
peak identification at 220 nm. Finally were analyzed
HPLC/MS/MS for metabolite structure identification.
The final determination about the structures of BZN phase
metabolites was obtained by HPLC/MS/MS.
Quantification of BZN was done in both urine
samples following a validated HPLC/UV method
previously developed (Marson et al., 2013). The analysis
for BZN and BZN metabolites peak identification was
done with a HPLC Merck-Hitachi LC-6200A and MerckHitachi UV/Vis L-4250 detector, adjusted in 220 nm.
Separation was carried out at room temperature using
a Lichrospher column (5 µm, 125 mm x 4.6 mm I.D.
RP 18). Samples were injected with a 20 µL sample loop.
Mobile phase was Water/Acetonitrile (75:25) and flow was
1 mL/min.
For metabolite structure identification, water/
Acetonitrile urine extracts were collected and analyzed by
using an Agilent liquid chromatograph series 1200 RRLC
with a diode array detector (DAD) in tandem with a Bruker
micrOTOF-QII electrospray source ionization (ESI)
mass spectrometer. Samples (5 µL) were separated on
a Phenomenex Luna C18 3µm 100A (100 x 2 mm), and
were eluted in isocratic mode with a mobile phase of 70%
water (0.1% formic acid): 30% acetonitrile at a flow rate of
0.2 mL/min. UV Detection wavelength was 220 nm. Their
m/z values were determined by positive ESI. Positive
ESI-tandem mass spectrometry (MS) was performed in
automatic mode. MS was carried out with a drying gas
temperature of 200°C, a drying gas flow of 8.0 liters/min,
a nebulizer gas pressure of 4 Bar, and a capillary voltage
of 150.0 V in full-scan mode in the m/z range of 50 to 900.
Urine samples and ethics statement

A twenty-four hour urine sample was obtained
from an 8 year old boy, 40 kg of weight, Chagas
disease pediatric patient under treatment with BZN
(5 mg/kg/d bid p.o.) for 60 days (100 mg Radanil
Braz. J. Pharm. Sci. 2020;56:e18034
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tablets, Roche, São Paulo, Brazil) (WHO, 2002;
Altcheh et al., 2011) in the context of a pediatric clinical
trial (Altcheh et al., 2014). The clinical protocol was
approved by the Ethics and Research Review Committee,
Buenos Aires Children´s Hospital “Ricardo Gutierrez”,
and the Argentine National Drug and Food Administration
(ANMAT), Ministry of Health, Argentina. Written
informed consent was obtained from parent or legally
authorized representatives as well as the assent from the
pediatric patient. The study was registered in clinicaltrials.
gov (#NCT00699387). The sample was collected on
day 15 after the start of treatment. The urine sample
was stored at –21°C until analysis. This patient, was
randomly selected from a prospective pediatric population
pharmacokinetic study of BNZ (Altcheh et al., 2014). The
treatment of this patient was in agreement with current
pediatric treatment guidelines (WHO, 2002).
A twenty-four hour urine sample was obtained from
a healthy adult male, volunteer, (47 years old, 80 kilograms
of weight) as a control for chromatographic parameters
and BZN stability studies on urine matrix. The volunteer
had not taken any medication for at least two weeks
before sample collection. After providing the control
sample, the same volunteer took one 400 mg dose of BZN
(5 mg/kg/d p.o.) at night, and a 24 hour urine sample was
collected. No pharmacodynamics or pharmacokinetics
was proposed for this sample collection, it was taken,
analogously as in the pediatric sample, in order to aisolate
and identify products of β-glucuronidase reaction that
could possibly be BZN metabolites. Written informed
consent was also obtained from this volunteer.
Urine sample pretreatment

Stability of BZN in urine at -21 °C was evaluated
by chromatographic analysis (Marson et al., 2013). Four
drug-free urine samples (5.00 mL each) were spiked with
BZN to attain a final concentration of 15 µg/mL; a control
sample without BNZ was kept under the same conditions.
All samples were stored at -21 °C, and thawed after 1, 15,
30 or 60 days, respectively. Every sample was treated after
storage with β-glucuronidase and injected into the HPLC.

Enzymatic reactions: Three 5.00 mL aliquots were
obtained in duplicates from the homogenized twentyfour hour urine samples (i.e. patient urine, volunteer
control urine and volunteer exposed to BNZ urine).
Aliquots (A) were treated with E. coli β-glucuronidase
enzyme; Aliquots (B) were treated with H. Pomatia
β-glucuronidase - arilsulfatase enzyme, and the aliquots
(C) were left enzymatically untreated as controls. All
three aliquots were processed together and under the same
experimental conditions. Reaction temperature (37 °C),
pH (6.5) amounts of enzyme and time of enzymatic
reaction followed the optimal conditions prescribed by
the supplier. Also, the amount of enzyme was calculated
considering an excess of enzyme respect to the total
amount of BZN dose. Temperature and pH were controlled
and registered during reaction with a manual thermometer
and a pH-meter respectively. For aliquot C, enzyme was
replaced by an equal volume of buffer phosphate (Table I).
The enzymatic reaction was stopped by
deproteinization with 500 µL of TCA 30% (w/v). Each
aliquot was separated into two portions for extraction at
two pH conditions: acidic (pH 3) and basic (pH 9). Acidic
conditions were obtained by addition of TCA 30% (w/v)
as described above, and basic conditions were obtained
by adding NaOH 10% (w/v). Subsequent BZN extraction
was done following a previously reported method for
HPLC/UV detection (Marson et al., 2013) which consists
in a liquid/liquid extraction of the urine samples with DCM
and anhydrous sodium sulfate (near saturation), by shaking
the mixture and centrifugation. The organic phases of
three consecutive liquid/liquid extraction procedures
were recovered together and evaporated to dryness
(Table II). The residue was resuspended in 800 µL of the
HPLC/UV mobile phase and injected into the
chromatographic system.

RESULTS
No significant BNZ concentration loss at 4 °C or
-21 °C was observed in the reference stock solution and
work solution after three and six months, respectively
(relative standard deviation RSD < 5%). In addition,

TABLE I - Experimental conditions for a three hour enzymatic assay for 5 mL urine samples

Enzyme volume (µL)
Buffer volume (µL)
Temperature (°C) range during reaction
pH during reaction range
Braz. J. Pharm. Sci. 2020;56:e18034

Aliquot A

Aliquot B

Aliquot C

10
36.5 - 37.5
6.52 ± 0.25

10
36.5 - 37.5
6.50 ± 0.30

10
36.5 - 37.5
6.53 ± 0.15
Page 3 / 8

M. E. Marson, F. G. Bournissen, J. Altcheh, G. Moscatelli, S. Moroni, G. E. Mastrantonio

TABLE II - Extraction procedure from urine samples after enzymatic treatment

Aliquot A
Aliquot B
Aliquot C
Urine blank control

Urine Vol
(µL)

Vol (µL) NaOH
(10% p/v)

1200
1200
1200
1200
1200
1200
1200
1200

30
80
30
80
35
70
35

no decomposition products were observed in the
chromatograms. Similarly, no significant BNZ loss was
observed in spiked control urine samples after 1, 15, 30
and 60 days of storage at -21°C (RSD < 5%). Also, no
potential interference signal was observed in the drug-free
control urine sample analyzed.
The BZN quantification results were 9.7 ± 0.3 µg/mL
and 25.2 ± 0.2 µg/mL for adult and pediatric samples
respectively, reﬂecting ∼3% and ∼7% of BNZ of the oral
doses. BZN was identified in all urine extracts in HPLC/
UV chromatograms. Enzymatically treated extracts
showed significantly different chromatographic profiles
from non-treated ones. Figure 1 shows representative
chromatograms obtained from the extracts analyzed, and
those enzymatically treated generated extracts with greater
amount of compounds identifiable by the chromatographic
system used. Retention time for BZN in all extracts was
(8.0 ± 0.1) minutes in HPLC/UV chromatograms.
Peaks (3 to 5) from each HPLC/UV chromatogram
were selected for MS and MS/MS identification, by visual
comparison between chromatogram profiles from those
extracts enzymatically and non-enzymatically treated.
Retention time for BZN in all extracts was
(17.4 ± 0.1) minutes in HPLC/MS/MS. Mass spectra
of the selected chromatographic peaks were evaluated,
and the principal molecular ions [M+H+] analyzed for
fragmentation patterns (+MS2) to confirm their structure.
Three compounds structurally related to BZN were
identified by HPLC/MS/MS: BZN-Na+ (m/z 283.08009),
N-amine-BZN (m/z 230.12307) and N-hydroxy-amineBZN (m/z 246.11702). BZN-Na+ is a technical artifact.
This adduct, formed during extracts dilution with mobile
phase, is differently resolved from the peak of free BNZ
(Hall, Wilkinson, 2012). Pharmacologically, BNZ-Na+ and
BNZ should be considered as the same substance. BNZ
(m/z 260.09847) was identified in all extracts, but N-amineBZN and N-hydroxy-amine-BZN were only observed in
Page 4 / 8

Vol (µL)
DCM /
extraction
400
400
400
400
400
400
400
400

Total DCM
extraction Vol
(µL)
1200
1200
1200
1200
1200
1200
1200
1200

Na2(SO4)2
(mg)

Extract pH

100
100
100
100
100
100
100
100

3
10
3
10
3
8
5
12

FIGURE 1 - Qualitative comparison of chromatographic
profiles: A Example of a non-enzymatically treated urine extract
chromatogram. B Example of an enzymatically treated urine
extract chromatogram.

those extracts with enzymatic treatment, suggesting that
they were excreted into urine in a conjugated form (i.e.
glucuronated). No significant differences were found
Braz. J. Pharm. Sci. 2020;56:e18034
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between extracts products from aliquots treated either
with β-glucuronidase or arilsulfatase enzymatic activity,
suggesting that the conjugated products are glucuronated
and not sulfated. When analyzing the intensity of the
signal at MS detection for the compounds identified, the
extraction procedure at basic conditions showed higher
results for N-amine-BZN than for acidic extracts.
Table III shows m/z of the compounds, molecular
formula (MF), insaturation number (IN), +MS2
fragmentation pattern and the extract in which they were
identified. The MS spectrum and MS/MS fragmentation
profiles for every structure are shown in Figure 2. The
new compounds identified had lower retention time
(10.7 ± 0.2) min for N-amine-BZN, and (11.2 ± 0.1) min
for N-hydroxi-amine-BZN compared to BZN.

DISCUSSION
BNZ is the most commonly used drug in Latin
America for the treatment of Chagas disease (Jannin, Villa,
2007). Trypanocidal activity was discovered empirically
more than four decades ago. The drug, a nitroimidazole
derivative, is believed to exert its biological activity
through the enzymatic bioreduction of the nitro group with
generation of reactive intermediates, a common mechanism
of action of nitroheterocyclic compounds that generally
act as pro-drugs and undergo activation to mediate their
cytotoxic effects (Castro, Mecca, Bartel, 2006).
On the other hand, it has been suggested that BNZ
serum concentrations do not appear to be related to the
appearance of serious ADRs in adult patients with Chagas
disease (Pinazo et al., 2013). This fact suggests a role of
circulating metabolites in BNZ toxicity at therapeutic
doses.

Unfortunately, little information is available on
BNZ metabolism or about the identity of its main human
metabolites, and apart from our previous work in which
we identified the plasma metabolite N-benzylacetamide
(Marson et al., 2015), no metabolite had previously been
identified in human beings. This situation is significantly
worse in the case of children.
In a murine model, enzymatic type II nitroreduction
of BZN is proposed to result in the BNZ amino derivative
(amine-BZN) through a series of sequential reactions
with very low redox potential (Walton, Workman,
1986). Also, a type I nitroreduction pathway is proposed
in which the latter derivative produces a highly toxic
intermediate for the parasite and the host. In the latter
case, parasite-specificity would be given by the parasiterestricted expression of type I nitroreductases (Hall,
Wilkinson, 2012). A T. cruzi BNZ metabolomics study
identified a large number of metabolites including
the amine derivative, and hydroxylamine derivative
(Trochine, Creek, 2014). Other researchers have proposed
N-oxide-molecules containing heterocycles as promising
compounds with tripanocidal activity (Boiani et al, 2010).
Observations from chromatographic profiles showed
a significant predominance of unchanged BZN compared
with other substances derived from this parent drug. These
compounds eluted before BZN, suggesting a more polar
behavior according to the chromatographic system used.
No differences in the profile of compounds identified were
observed between the samples from the adult healthy
volunteer and those from the pediatric patient. Also, the
extraction procedure at different pH conditions did not
show qualitatively different chromatographic profiles,
except for the case of N-amine-BZN, where signal intensity
found was around double from acidic ones. This suggests

TABLE III - HPLC/MS/MS identified compounds related to BZN, their m/z and molecular formula (MF), instauration number (IN),
and the extract in which they were identified.

+MS2 fragmentation pattern:
Structure Named
MF & m/z
C12H12N3O (214.09749)
C9H10NO (148.07569)
BZN
C7H7O (107.04914)
C7H7 (91.05423)
Same as above
BZN Na+

m/z

MF

IN

260.09847

C12H12N4O3

9

283.08009

C12H12N4O3Na

9

230.12307

C12H14N4O

8

C5H6N3O (124.05054)

NH2-BZN

246.11702

C12H14N4O2

8

C5H6N3O2 (140.04545)
C4H6N3 O (112.05054)
C7H7 (91.05423)

NH-OH-BZN

Braz. J. Pharm. Sci. 2020;56:e18034

Extract presence

In all extracts
In all extracts
Only in enzymatically
treated extracts
Only in enzymatically
treated extracts
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FIGURE 2 - A Amine-BNZ(H)+ MS detection (m/z 231.12245; Retention time 10.7 minutes), scanning 50 to 800 m/z; B +MS2 for

m/z 231.12532 and Retention time of 10.7 minutes; C N-hydroxi-amine-BZN(H)+ MS detection (m/z 247.11702; Retention time
11.1-11.2 min), scanning 50 to 800 m/z; D +MS2 for m/z 247.12218 and Retention time of 11.1 minutes.

that for this compound it would be better to select basic
conditions for the extraction process. As we did not have
these compounds synthesized in conditions so as to be used
as an analytical standard, accurate quantification was not
done. In general terms, these compounds could be extracted
either in acidic or basic conditions, but we recommend
a basic extraction for better recovery of N-amine-BZN.
Page 6 / 8

Based on the mass spectrometry detection and identification
results, we conclude that the amine-BZN and N-hydroxiamine-BZN could be phase I metabolic products of BNZ,
excreted in urine as conjugates (as they only were present in
glucuronidase-treated extracts). As none of the metabolites
were identified in the enzymatically untreated extracts it is
possible to conclude that these molecules were eliminated
Braz. J. Pharm. Sci. 2020;56:e18034
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FIGURE 3 - Proposed metabolic pathway of BZN and its metabolites production.

in their N-glucuronides forms. Although these results are
limited by the small number of samples studied, they offer
interesting new hypotheses that need to be confirmed. We
present in Figure 3 a hypothetic metabolic pathway from
BZN to these compounds.

Boiani M, Piacenza L, Hernández P, Boiani L, Cerecetto
H, González M, Denicola A. Mode of action of Nifurtimox
and N-oxide-containing heterocycles against Trypanosoma
cruzi: Is oxidative stress involved? Biochem Pharmacol.
2010;79(12):1736-45. doi: 10.1016/j.bcp.2010.02.009.

CONCLUSION

Castro JA, Mecca MM, Bartel LC. Toxic side effects of drugs
used to treat Chagas´ disease (American trypanosomiasis). Hum
Exp Toxicol. 2006;25(8):471–9.

In this work, for the first time, two BZN metabolites
(N-amine-BZN and N-hydoxy-amine-BZN) are identified
in human urine samples. These metabolites are likely
phase I metabolites, product of xenobiotics metabolic
reactions that convert the BNZ nitro group into the amine
or N-hydroxy-amine group, respectively. N-glucuronides
conjugates are an example of phase II reaction products
that increase the polarity of the molecules to facilitate
excretion into urine. This work provides experimental
evidence of benznidazole N-reduced metabolites and its
renal excretion in N-glucuronide form.
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